Multiplex Assays Market by Product & Service, Type, Technology, Application, End User

List of Tables

The Multiplex Assays Market is projected to reach USD 6.88 billion by 2030 from USD 3.59 billion in 2022, at a CAGR of 8.46% during the forecast period.

Global Multiplex Assays Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 3.59 billion
Estimated Year Value [2023]	USD 3.89 billion
Forecast Year Value [2030]	USD 6.88 billion
CAGR (%)	8.46%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Multiplex Assays Market.

Based on Product & Service, market is studied across Consumables, Instruments, and Software & Services. The Consumables is projected to witness significant market share during forecast period.

Based on Type, market is studied across Cell-Based Multiplex Assays, Nucleic Acid Multiplex Assays, and Protein Multiplex Assays. The Nucleic Acid Multiplex Assays is further studied across Bead-Based Nucleic Acid Assays and Planar Nucleic Acid Assays. The Protein Multiplex Assays is further studied across Bead-Based Protein Assays and Planar Protein Assays. The Nucleic Acid Multiplex Assays is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time Flow Cytometry, and Multiplex Real-Time PCR. The Multiplex Real-Time Flow Cytometry is projected to witness significant market share during forecast period.

Based on Application, market is studied across Clinical Diagnostics and Research & Development. The Clinical Diagnostics is further studied across Autoimmune Diseases, Cancer, Cardiovascular Diseases, Infectious Diseases, Metabolism & Endocrinology Disorders, and Nervous System Disorders. The Research & Development is further studied across Biomarker Discovery & Validation and Drug Discovery & Development. The Clinical Diagnostics is projected to witness significant market share during forecast period.

Based on End User, market is studied across Hospitals & Research Institutes, Pharmaceutical & Biotechnology Companies, and Reference Laboratories. The Hospitals & Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Multiplex Assays Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Multiplex Assays Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Multiplex Assays Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, Agilent Technologies, Inc., Antigenix America, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cayman Chemical Company, Charles River Laboratories, Enfer Group, Enzo Life Sciences, Inc., Eve Technologies Corp., Flagship Biosciences Inc., Future Diagnostics Solutions B.V., Gnome Diagnostics and Gnome Sciences, Illumina, Inc., Merck KGaA, MESO SCALE DIAGNOSTICS, LLC, Novatein Biosciences Inc., PerkinElmer, Inc., Protavio Ltd., Siemens Healthineers AG, Solis BioDyne OU, and Thermo Fisher Scientific Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Multiplex Assays Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Multiplex Assays Market?

3. What is the competitive strategic window for identifying opportunities in the Multiplex Assays Market?

4. What are the latest technology trends and regulatory frameworks in the Multiplex Assays Market?

5. What is the market share of the leading vendors in the Multiplex Assays Market?

6. Which modes and strategic moves are suitable for entering the Multiplex Assays Market?

Product Code: MRR-8201ABF20BDA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Multiplex Assays Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising chronic and infectious disease and rapid shift towards early diagnosis
  - 5.1.1.2. Surge in usage of personalized-precision medications
  - 5.1.1.3. Growing application of multiple assays in drug development
- 5.1.2. Restraints
  - 5.1.2.1. Associated shear complexity of multiplex assays and high cost of instruments
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging technology of multiplexing in clinical diagnostics
  - 5.1.3.2. Potential adoption of automated instruments and equipment in clinical practice
- 5.1.4. Challenges
  - 5.1.4.1. Shortage of skilled and experienced healthcare professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Multiplex Assays Market, by Product & Service

6.1. Introduction
6.2. Consumables
6.3. Instruments
6.4. Software & Services

7. Multiplex Assays Market, by Type

7.1. Introduction
7.2. Cell-Based Multiplex Assays
7.3. Nucleic Acid Multiplex Assays
- 7.4.1. Bead-Based Nucleic Acid Assays
- 7.4.2. Planar Nucleic Acid Assays
7.4. Protein Multiplex Assays
- 7.5.1. Bead-Based Protein Assays
- 7.5.2. Planar Protein Assays

8. Multiplex Assays Market, by Technology

8.1. Introduction
8.2. Flow Cytometry
8.3. Fluorescence Detection
8.4. Luminescence
8.5. Multiplex Real-Time Flow Cytometry
8.6. Multiplex Real-Time PCR

9. Multiplex Assays Market, by Application

9.1. Introduction
9.2. Clinical Diagnostics
- 9.3.1. Autoimmune Diseases
- 9.3.2. Cancer
- 9.3.3. Cardiovascular Diseases
- 9.3.4. Infectious Diseases
- 9.3.5. Metabolism & Endocrinology Disorders
- 9.3.6. Nervous System Disorders
9.3. Research & Development
- 9.4.1. Biomarker Discovery & Validation
- 9.4.2. Drug Discovery & Development

10. Multiplex Assays Market, by End User

10.1. Introduction
10.2. Hospitals & Research Institutes
10.3. Pharmaceutical & Biotechnology Companies
10.4. Reference Laboratories

11. Americas Multiplex Assays Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Multiplex Assays Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Multiplex Assays Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories
- 15.1.2. Abcam PLC
- 15.1.3. Agilent Technologies, Inc.
- 15.1.4. Antigenix America, Inc.
- 15.1.5. Becton, Dickinson and Company
- 15.1.6. Bio-Rad Laboratories, Inc.
- 15.1.7. Bio-Techne Corporation
- 15.1.8. Cayman Chemical Company
- 15.1.9. Charles River Laboratories
- 15.1.10. Enfer Group
- 15.1.11. Enzo Life Sciences, Inc.
- 15.1.12. Eve Technologies Corp.
- 15.1.13. Flagship Biosciences Inc.
- 15.1.14. Future Diagnostics Solutions B.V.
- 15.1.15. Gnome Diagnostics and Gnome Sciences
- 15.1.16. Illumina, Inc.
- 15.1.17. Merck KGaA
- 15.1.18. MESO SCALE DIAGNOSTICS, LLC
- 15.1.19. Novatein Biosciences Inc.
- 15.1.20. PerkinElmer, Inc.
- 15.1.21. Protavio Ltd.
- 15.1.22. Siemens Healthineers AG
- 15.1.23. Solis BioDyne OU
- 15.1.24. Thermo Fisher Scientific Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing